Top 6 newest treatment for psoriatic arthritis in 2022

Below are the best information and knowledge on the subject newest treatment for psoriatic arthritis compiled and compiled by our own team oanhthai:

1. Psoriatic Arthritis and New First-Line Treatment Options: Interleukin-17 Inhibitors

Author: www.medicalnewstoday.com

Date Submitted: 10/06/2020 01:10 AM

Average star voting: 5 ⭐ ( 95634 reviews)

Summary: A comparison of secukinumab, ixekizumab, and brodalumab as alternative treatments for psoriatic arthritis, including articular manifestations.

Match with the search results: , a new interleukin blocker, for the treatment of PsA in 2020. It is the first treatment for PsA that specifically targets interleukin-23 (IL-23), which is a cytokine associated with inflammation in PsA….. read more

Psoriatic Arthritis and New First-Line Treatment Options: Interleukin-17 Inhibitors

2. 5 Questions for a Scientist Who’s Working to Uncover New Treatments for Psoriatic Arthritis

Author: www.psoriasis.org

Date Submitted: 05/24/2021 07:23 AM

Average star voting: 4 ⭐ ( 10306 reviews)

Summary: We spoke with Dr. Daniel Cua, known as “the father” in his field of study, about his work uncovering new psoriatic arthritis treatments. Read our interview.

Match with the search results: New Treatment for PsA. The U.S. FDA approves upadacitinib for the treatment of adults with active psoriatic arthritis. December 20, 2021….. read more

5 Questions for a Scientist Who's Working to Uncover New Treatments for Psoriatic Arthritis

3. Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis

Author: www.arthritis.org

Date Submitted: 11/06/2020 02:04 PM

Average star voting: 3 ⭐ ( 70773 reviews)

Summary: Psoriasis, an inflammatory skin disease, and psoriatic arthritis (PsA), an inflammatory arthritis, share clinical, genetic, and pathogenic factors and may be summed as one disease, the psoriatic disease. Interleukin (IL)-17 plays a major role in the development of both psoriasis and PsA. IL-23 is important in the proliferation and maintenance of IL-17, and therefore, cytokines of the IL-23/IL-17 axis attracted much interest as therapeutic targets in psoriasis and PsA. Therapeutic agents targeting the cytokine IL-23/IL-17 axis have been proved very effective in psoriasis and PsA, some are already in the therapeutic armamentarium and others are in the development. Some agents target IL-23 and others IL-17 and include anti-IL-12/IL-23 p40 (ustekinumab, briankizumab), anti-IL-23p19 (guselkumab, tildrakizumab, risankizumab, brazikumab, mirikizumab), anti-IL-17A (secukinumab, ixekizumab), dual anti-IL-17A and anti-IL-17F (bimekizumab), or anti-IL-17 receptor (brodalumab) monoclonal antibodies. Janus tyrosine kinase(JAK) inhibitors also directly affect IL-23 and thus IL-17. After the first generation pan-JAK inhibitors have been shown efficacy (tofacitinib, baricitinib) new generation selective JAK inhibitors (filgotinib, upadacitinib) are under investigation in psoriasis and PsA.

Match with the search results: Biologic abatacept (Orencia) was approved in 2017 to treat psoriatic arthritis in adults. It was already approved for rheumatoid arthritis (RA) and for one ……. read more

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis

4. Key discovery in psoriatic arthritis points way for developing targeted treatments

Author: www.webmd.com

Date Submitted: 08/05/2020 10:16 PM

Average star voting: 4 ⭐ ( 35640 reviews)

Summary: The strongest evidence yet of a single cause for psoriatic arthritis has been discovered by researchers. The disease may be activated by the same trigger in different patients which, if identified, could move towards creating therapies that would prevent psoriatic arthritis, and potentially providing a cure.

Match with the search results: Apremilast (Otezla) is a new kind of drug for long-term inflammation diseases like psoriatic arthritis. It’s a pill that works by blocking a ……. read more

Key discovery in psoriatic arthritis points way for developing targeted treatments

5. New Psoriatic Arthritis Treatments 2021

Author: www.everydayhealth.com

Date Submitted: 02/23/2020 10:21 PM

Average star voting: 5 ⭐ ( 23929 reviews)

Summary: What is Psoriatic Arthritis?
What are Psoriatic Arthritis symptoms?
Treatment for Psoriatic Arthritis
What are Psoriatic Arthritis medicine side effects?
What are new Psoriatic Arthritis treatments?
Why access Psoriatic Arthritis treatments with TheSocialMedwork?

Article last updat

Match with the search results: What’s New Two studies presented at the conference found that risankizumab (Skyrizi) is effective against PsA. Currently the prescription ……. read more

New Psoriatic Arthritis Treatments 2021

6. U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis | AbbVie News Center

Author: www.dermatologytimes.com

Date Submitted: 09/20/2019 06:56 PM

Average star voting: 4 ⭐ ( 91129 reviews)

Summary:

Match with the search results: Dermavant Sciences announced on June 3 that it had submitted a new drug application to the FDA for tapinarof for the treatment of mild, ……. read more

U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis | AbbVie News Center

Trả lời

Email của bạn sẽ không được hiển thị công khai.